In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL). This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...
Read MoreLibrary Item Posts on Medivizor
Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia
In a nutshell This study aimed to compare the outcomes of allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) for patients with acute promyelocytic leukemia (APL) in second complete remission (CR2). This study concluded that autoHSCT resulted in better outcomes for these patients. Some background...
Read MoreNivolumab improves survival in patients with non-small cell lung cancer in the long-term.
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read MoreCan exercise improve chemotherapy symptoms in patients with lung cancer?
In a nutshell This article looked at the effectiveness of exercise in improving physical and mental outcomes in patients with lung cancer undergoing chemotherapy (CT). The authors found that supervised exercise improved strength, lung function, and quality of life (QoL) in these patients. Some background Lung cancer is one of the most common...
Read MoreIs nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?
In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...
Read MoreComparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.
In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...
Read MoreIs omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?
In a nutshell This study looked at the use of omarigliptin (Marizev) in insulin-treated patients with uncontrolled type 2 diabetes (T2D). It found that omarigliptin was well-tolerated and improved blood glucose control. Some background Type 2 diabetes (T2D) is usually treated initially with diet, exercise, and...
Read MoreCan a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?
In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite. Some background...
Read MoreComparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas
In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...
Read MoreReduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors
In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that SGLT-2is may reduce the risk of heart failure hospitalizations in these patients. Some background Patients with T2D have a higher risk of developing...
Read MoreEvaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.
In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM). The authors concluded that this regimen provided very good...
Read MoreUltra-hypofractionated radiotherapy leads to similar patient-reported quality of life outcomes versus conventionally fractionated radiotherapy for prostate cancer
In a nutshell This study compared the patient-reported quality of life outcomes between conventionally fractionated radiation treatment (CFRT) and ultra-hypofractionated radiation treatment (UHFRT) in patients with localized prostate cancer. The data showed that both radiotherapy techniques led to similar long-term outcomes. Some background Radiation...
Read More